Call for Abstract
Scientific Program
13th International Conference on Metabolomics and Systems Biology, will be organized around the theme “Scientific Advances In Metabolomics and Systems Biology”
Euro Metabolomics 2018 is comprised of 17 tracks and 97 sessions designed to offer comprehensive sessions that address current issues in Euro Metabolomics 2018.
Submit your abstract to any of the mentioned tracks. All related abstracts are accepted.
Register now for the conference by choosing an appropriate package suitable to you.
- Track 1-1Metabolite identification and analysis
- Track 1-2Metabolomics databases
- Track 1-3Software workflow for metabolomics: Targeted and non targeted screening and validation
- Track 2-1Cancer immunotherapy
- Track 2-2Gene therapy
- Track 2-3Targeted therapeutics
- Track 2-4Novel approaches to cancer therapeutics
- Track 2-5Active immunotherapies
- Track 2-6Metabolic profiling in cancer
- Track 2-7Applications of metabolomics in oncology
- Track 3-1Metabolite platform for validation of biomarkers
- Track 3-2Biomarkers in drug development
- Track 3-3Disease related biomarkers
- Track 3-4Imaging biomarkers
- Track 3-5Metabolomics in biomarker discovery
- Track 4-1Genome-scale modelling & flux balance analysis
- Track 4-2In silico design of novel pathways
- Track 4-3Signal transduction
- Track 4-4Architecture of human metabolome
- Track 4-5Computational data analysis in metabolomics
- Track 4-6Metabolic flux analysis and metabolic models
- Track 4-7Metabolic network simulation
- Track 5-1Regenerative medicine and predictive medicine
- Track 5-2Inborn errors of metabolism (IEM)
- Track 5-3Nutraceuticals
- Track 5-4Pharmacometabolomics and precision medicine
- Track 5-5Clinical applications of precision medicine
- Track 5-6Precision medicine for mental disorders
- Track 5-7Molecular biological profiling
- Track 6-1Drug metabolism during drug design and development
- Track 6-2Metabolites in identification of drug targets
- Track 6-3Metabonomics in preclinical pharmaceutical discovery and development
- Track 6-4Toxicology and drug metabolism
- Track 6-5QSAR and ligand-receptor models
- Track 6-6Applications in drug development
- Track 7-1Food Metabolome
- Track 7-2Food and nutritional metabolomics
- Track 7-3Dietary metabolites and cellular metabolism
- Track 7-4Food safety and contamination assessment using metabolomics
- Track 7-5Applications of metabolomics to food processing
- Track 8-1Membrane lipidomics and cellular lipidomics
- Track 8-2Lipid associated networks and pathways
- Track 8-3Lipid extraction and bio-fluids
- Track 8-4Bioinformatics tools for lipidomics research
- Track 8-5Lipid molecular databases
- Track 8-6Neutral Lipidomics
- Track 8-7Shotgun Lipidomics
- Track 9-1Metabolomics for exposomics
- Track 9-2Green systems biology
- Track 9-3Toxicometabolomics
- Track 9-4Microbiome-related metabolome
- Track 9-5Environmental metabolome
- Track 9-6Metabolomics of genetically modified crops
- Track 9-7Nutrigenomics and plant functional genomics
- Track 10-1RNA-seq technology
- Track 10-2Next generation sequencing (NGS) technologies
- Track 10-3Gene Expression Profiling and Epigenetics
- Track 10-4Transcriptome and proteome analysis
- Track 10-5RNAi gene silencing technology
- Track 11-1Systems biology methods to characterize biological systems
- Track 11-2Multicellular systems biology
- Track 11-3Quantitative systems pharmacology
- Track 11-4Mathematical biology
- Track 11-5Pathways and networks
- Track 11-6Modelling and simulation tools in systems biology
- Track 12-1Machine learning and pattern recognition
- Track 12-2Knowledge discovery and data mining techniques
- Track 12-3Bioinformatics and cheminformatics
- Track 12-4Sequence motifs and alignments
- Track 12-5Hidden markov model
- Track 12-6Sequencing algorithms
- Track 12-7Stochastic modelling
- Track 13-1Targeted metabolic profiles
- Track 13-2Mass spectrometry
- Track 13-3Capillary electrophoresis–mass spectrometry (CE–MS)
- Track 13-4Ratio analysis of NMR/MS
- Track 13-5Nuclear magnetic resonance (NMR)
- Track 13-6Gas chromatography–mass spectrometry (GC–MS)
- Track 13-7Liquid chromatography–mass spectrometry (LC–MS)
The latest addition of “omics” disciplines is Metabolomics and it has shown rapid growth in the application to human health research because of major advancements in measurement and analysis techniques. Metabolomics has unique advantages in systems biology and biomarker discovery. The next generation of analysis techniques promises even richer and more complete analysis capabilities that will enable earlier clinical diagnosis, drug refinement, and personalized medicine. The advancements in methodologies and statistical analysis that are enhancing and improving the performance of metabolomics is presented along with highlights of some recent successful applications
- Track 14-1Spatial metabolomics
- Track 14-2Network and pathway analysis for metabolomics
- Track 14-3Chemical and structural characterization of new metabolites
- Track 14-4Chemometrics, statistical analysis, and other approaches to data analysis
- Track 14-5Novel sensors and instrumentation for detecting metabolites
- Track 14-6Computational MS
- Track 14-7Databases
- Track 15-1Metabolic and endocrine science
- Track 15-2Metabolomics in diabetes
- Track 15-3Metabolomics in neuroscience and neurology
- Track 15-4Metabolomics in cardiovascular diseases
They are a vital direct source of confirmation in pharmaceutical and a device regularly utilized as a part of practice to craft data and create a more extended quest for proof. A decent case report will be vibrant about the significance of the perception being accounted for. In addition to the “evidence of what happened”, single or multiple cases are an important origin for further and more advanced research on diagnosis, treatment adequacy, reasons and results of ailment. Case reports might be first to give signs in differentiating another ailment or unfriendly wellbeing impact from a presentation.
- Track 17-1Cardiovascular diseases
- Track 17-2Cancer
- Track 17-3Auto immune diseases
- Track 17-4Neurodegenerative diseases
- Track 17-5Metabolomic diseases
- Track 17-6Clinical case reports
- Track 17-7Diabetes